Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
Interventions: LY2382770, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 25 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 28
States / cities: Phoenix, Arizona • Inglewood, California • Los Angeles, California + 25 more

Conditions: Fatigue, Locally Advanced or Metastatic Breast Cancer
Interventions: Reparixin, Placebo; Drug
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Cary, North Carolina • Nashville, Tennessee

Conditions: Eosinophilic Esophagitis
Interventions: EUR-1100, placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 4 more

Conditions: Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure, Left Ventricular Ejection Fraction, Pharmacokinetics, Echocardiogram
Interventions: Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 38
States / cities: Mobile, Alabama • Costa Mesa, California • Fresno, California + 34 more

Conditions: Chronic Migraine or Episodic Migraine
Interventions: Placebo, AMG 301; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 21
States / cities: Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more

Conditions: Hypertension
Interventions: ramipril, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 39
States / cities: Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 33 more

Conditions: Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Colorectal Cancer, Renal Cancer, Melanoma, Sarcoma
Interventions: Video Education, Genetic Counseling; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteer
Interventions: BIIB091, Moxifloxacin, BIIB091-matched Placebo, Moxifloxacin-matched Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Essential Tremor
Interventions: 1-Octanol; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Older Adult
Interventions: OSC-; Behavioral
Lead sponsor: Brigham Young University; Other
Eligibility: 65 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Provo, Utah

Conditions: Liver Cirrhosis, Hepatic Cirrhosis
Interventions: IDN-6556, Placebo; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 28
States / cities: Birmingham, Alabama • La Jolla, California • Loma Linda, California + 21 more

Conditions: HiV1- Positive
Interventions: Abacavir/Lamivudine; Drug
Lead sponsor: Therapeutic Concepts; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prematurity
Interventions: Umbilical Cord Milking; Procedure
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years and older · Female only
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Venous Malformations, Lymphatic Malformations, Klippel-Trenaunay Syndrome, CLOVES Syndrome
Interventions: KP-001, Placebo; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 2 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Progressive Multiple Sclerosis, Fatigue
Interventions: N-acetyl cysteine, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple System Atrophy (MSA)
Interventions: ONO-2808, Placebo; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 30
States / cities: Fountain Valley, California • Los Angeles, California • Palo Alto, California + 23 more

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: Oxaliplatin, Leucovorin, Fluorouracil, Ziv-aflibercept; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Mild to Moderate Persistent Asthma
Interventions: Activation Energy Serum; Dietary Supplement
Lead sponsor: California Allergy and Asthma Medical Group, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Adult
Interventions: BMS-986142, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Suicidal Ideation
Interventions: Nabilone, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prader-Willi Syndrome
Interventions: Pitolisant oral tablets, Placebo oral tablet; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 6 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 13
States / cities: San Diego, California • San Ramon, California • Santa Monica, California + 10 more

Conditions: Preterm Infant
Interventions: Therapist skin-to-skin Care, Contingent parent's voice exposure, Parental skin-to-skin care, Recorded parent's voice; Behavioral · Device
Lead sponsor: Emory University; Other
Eligibility: 32 Weeks to 36 Weeks
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia • Columbus, Ohio

Conditions: Healthy Volunteers
Interventions: AZD2373 subcutaneous injection, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Clostridium Difficile Infection
Interventions: Ridinilazole, Fidaxomicin; Drug
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Laguna Hills, California • Ventura, California • Idaho Falls, Idaho + 2 more

Search by objective public record fields.

A Study in Participants With Diabetic Kidney Disease

To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer

Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

Video Education With Result Dependent dIsclosure

A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants

1-Octanol to Treat Essential Tremor

Heart Rate Variability Biofeedback in Older Adults

A Study of IDN-6556 in Subjects With Liver Cirrhosis

Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy

Umbilical Cord Milking on the Reduction of Red Blood Cell Transfusion Rates in Infants

A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES Syndrome

A Study of Oxidative Pathways in MS Fatigue

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.

Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects

Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Trial to Improve Multisensory Neural Processing, Language & Motor Outcomes in Preterm Infants

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)